zDHHC12 is responsible for mediating S-palmitoylation of CLDN3 at amino acid positions C181, C182, and C184. This modification contributes to the accurate localization and stabilization of CLDN3 on the plasma membrane, particularly in ovarian cancer. Additionally, zDHHC12 acts as an inhibitor of the NLRP3 inflammasome by facilitating the palmitoylation of NLRP3, ultimately promoting its degradation. Here, CLDN3 is linked to ovarian cancer.